NCT04579471 Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study
| NCT ID | NCT04579471 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Covid19 |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2020-07-01 |
| Primary Completion | 2021-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2020-07-01 with a primary completion date of 2021-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.
Eligibility Criteria
Inclusion Criteria: * all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent Exclusion Criteria: * age under 18 years
Contact & Investigator
Jef Verbeek, MD, PhD
PRINCIPAL INVESTIGATOR
UZ Leuven
Frequently Asked Questions
Who can join the NCT04579471 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Covid19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04579471 currently recruiting?
Yes, NCT04579471 is actively recruiting participants. Contact the research team at jef.verbeek@uzleuven.be for enrollment information.
Where is the NCT04579471 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT04579471 clinical trial?
NCT04579471 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Jef Verbeek, MD, PhD at UZ Leuven. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.